On July 30, 2026, the clinical trial registry updated the status of a Phase 3 study of retatrutide (LY3437943) to completed. The trial, titled "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease," is registered under identifier NCT05882045. It is listed as a Phase 3 study evaluating retatrutide in participants with obesity and cardiovascular disease. The registry entry reflects a change in trial status only, marking the study as completed as of the date given. No results, outcomes, or safety findings are included in this status update. This brief does not report on efficacy, adverse events, or any conclusions drawn from the trial, as none were provided in the available data. Readers seeking further detail on this specific study can consult the official registry listing for the full trial record. For general background on retatrutide, including its regulatory status and development history, readers can refer to the compound overview.
Retatrutide Phase 3 Trial in Obesity and CVD Marked Completed
See the full retatrutide overview
Source: https://clinicaltrials.gov/study/NCT05882045